Eloxx Pharmaceuticals (NASDAQ:ELOX) Receives “Buy” Rating from Guggenheim

Eloxx Pharmaceuticals (NASDAQ:ELOX)‘s stock had its “buy” rating reaffirmed by stock analysts at Guggenheim in a research report issued on Monday,Benzinga reports. They presently have a $43.00 price target on the stock. Guggenheim’s target price points to a potential upside of 104.96% from the company’s current price.

Other equities analysts also recently issued reports about the company. Lucid Cap Mkts upgraded Eloxx Pharmaceuticals to a “strong-buy” rating in a research report on Thursday. Wall Street Zen upgraded Eloxx Pharmaceuticals to a “hold” rating in a report on Saturday, August 1st. Lifesci Capital started coverage on shares of Eloxx Pharmaceuticals in a research note on Wednesday, July 22nd. They set an “outperform” rating and a $40.00 price objective for the company. Finally, Weiss Ratings assumed coverage on shares of Eloxx Pharmaceuticals in a report on Friday, August 14th. They set a “sell (d)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Eloxx Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $41.50.

Eloxx Pharmaceuticals Stock Performance

Shares of Eloxx Pharmaceuticals stock opened at $20.98 on Monday. Eloxx Pharmaceuticals has a fifty-two week low of $8.20 and a fifty-two week high of $23.40. The stock has a market cap of $84.76 million, a price-to-earnings ratio of -13.62 and a beta of -1,863.11. The business’s fifty day simple moving average is $14.32.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.